Table 2.
Use of cinacalcet hydrochloride and concomitant medications for secondary hyperparathyroidism
| Group S |
Group L |
|||||||
|---|---|---|---|---|---|---|---|---|
| Baseline (n = 56) | Week 12 (n = 55) | Week 26 (n = 53) | Week 52 (n = 49) | Baseline (n = 25) | Week 12 (n = 24) | Week 26 (n = 21) | Week 52 (n = 19) | |
| Cinacalcet hydrochloride (mg/d) | 29.3 ± 9.9 | 32.7 ± 13.2 | 36.7 ± 14.5 | 28.7 ± 10.0 | 35.7 ± 19.9 | 42.8 ± 20.9 | ||
| Intravenous vitamin D sterols | ||||||||
| subjects (%) | 71 | 65 | 62 | 65 | 72 | 54 | 52 | 68 |
| calcitriol dose equivalentsa (μg/wk) | 2.18 ± 1.07 | 2.28 ± 1.16 | 2.32 ± 1.25 | 2.39 ± 1.33 | 3.06 ± 1.65 | 3.11 ± 1.37 | 2.86 ± 1.30 | 3.32 ± 2.00 |
| Oral vitamin D sterol use (%) | 21 | 25 | 25 | 29 | 12 | 21 | 29 | 32 |
| Calcium carbonate | ||||||||
| subjects (%) | 59 | 73 | 79 | 82 | 40 | 75 | 62 | 53 |
| calcium carbonate dose (mg/d) | 2506 ± 1067 | 2737 ± 1144 | 2779 ± 1370 | 2755 ± 1408 | 2030 ± 868 | 2044 ± 805 | 2023 ± 831 | 2150 ± 1156 |
| Sevelamer hydrochloride | ||||||||
| subjects (%) | 68 | 64 | 64 | 65 | 72 | 67 | 67 | 63 |
| sevelamer hydrochloride dose (mg/d) | 3026 ± 1048 | 3100 ± 980 | 2977 ± 1019 | 2930 ± 1069 | 3167 ± 1222 | 2878 ± 1224 | 2942 ± 1351 | 2625 ± 1517 |
Plus-minus values are mean ± SD.
a
1.5 μg of calcitriol = 10 μg of maxacalcitol.